Natarajan Sethuraman Entrada Therapeutics, Inc. (TRDA) insider trading activity

TRDA Quotes by TradingView

Natarajan Sethuraman is President, Research & Develop. of Entrada Therapeutics, Inc.. Currently has a direct ownership of 183,216 shares of TRDA, which is worth approximately $3.14 Million. The most recent transaction as insider was on Oct 16, 2024, when has been sold 600 shares (Common Stock) at a price of $18.0 per share, resulting in proceeds of $10,800. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 183K
2.96% 3M change
9.58% 12M change
Total Value Held $3.14 Million

Natarajan Sethuraman Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 16 2024
SELL
Open market or private sale
$10,800 $18.0 p/Share
600 Reduced 0.33%
183,216 Common Stock
Sep 09 2024
SELL
Open market or private sale
$39,867 $15.09 p/Share
2,642 Reduced 1.42%
183,816 Common Stock
Sep 06 2024
SELL
Open market or private sale
$9,144 $15.24 p/Share
600 Reduced 0.32%
186,458 Common Stock
Sep 05 2024
SELL
Payment of exercise price or tax liability
$2,526 $15.13 p/Share
167 Reduced 0.09%
187,058 Common Stock
Sep 04 2024
SELL
Payment of exercise price or tax liability
$14,726 $15.42 p/Share
955 Reduced 0.51%
187,225 Common Stock
Sep 03 2024
SELL
Payment of exercise price or tax liability
$10,651 $16.8 p/Share
634 Reduced 0.34%
188,180 Common Stock
Jul 15 2024
SELL
Open market or private sale
$11,484 $18.0 p/Share
638 Reduced 0.34%
188,814 Common Stock
Jul 12 2024
SELL
Open market or private sale
$10,800 $18.0 p/Share
600 Reduced 0.32%
189,452 Common Stock
May 20 2024
SELL
Open market or private sale
$146,963 $15.19 p/Share
9,675 Reduced 4.84%
190,052 Common Stock
May 17 2024
SELL
Open market or private sale
$125,737 $15.14 p/Share
8,305 Reduced 3.99%
199,727 Common Stock
May 16 2024
SELL
Open market or private sale
$15,000 $15.0 p/Share
1,000 Reduced 0.48%
208,032 Common Stock
Mar 05 2024
SELL
Payment of exercise price or tax liability
$18,481 $12.28 p/Share
1,505 Reduced 0.71%
209,032 Common Stock
Mar 04 2024
SELL
Payment of exercise price or tax liability
$9,816 $12.9 p/Share
761 Reduced 0.36%
210,537 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
44,100 Added 17.27%
211,298 Common Stock
Sep 05 2023
SELL
Payment of exercise price or tax liability
$6,492 $14.46 p/Share
449 Reduced 0.27%
167,198 Common Stock
Sep 01 2023
BUY
Grant, award, or other acquisition
-
14,200 Added 7.81%
167,647 Common Stock
Jul 11 2023
SELL
Open market or private sale
$267,930 $18.04 p/Share
14,852 Reduced 8.82%
153,447 Common Stock
Jul 10 2023
SELL
Open market or private sale
$54,468 $18.0 p/Share
3,026 Reduced 1.77%
168,299 Common Stock
Apr 17 2023
SELL
Open market or private sale
$71,298 $18.0 p/Share
3,961 Reduced 2.26%
171,325 Common Stock
Mar 02 2023
SELL
Payment of exercise price or tax liability
$12,272 $11.6 p/Share
1,058 Reduced 0.56%
189,486 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
28,400 Added 12.97%
190,544 Common Stock
Sep 01 2022
BUY
Grant, award, or other acquisition
-
5,794 Added 3.45%
162,144 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
11,588 Added 6.9%
156,350 Common Stock
NS

Natarajan Sethuraman

President, Research & Develop.
Boston, MA

Track Institutional and Insider Activities on TRDA

Follow Entrada Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRDA shares.

Notify only if

Insider Trading

Get notified when an Entrada Therapeutics, Inc. insider buys or sells TRDA shares.

Notify only if

News

Receive news related to Entrada Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on TRDA